International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-4 doi: 10.5281/zenodo.13336178
Original Research Article
Serum Sodium as a Prognostic Marker in Chronic Decompensated Cirrhosis of the Liver
Published
Aug. 27, 2024
Abstract

Background: Serum sodium levels have been recognized as a prognostic marker in chronic liver disease, particularly in decompensated cirrhosis. This study aimed to investigate the association between serum sodium levels and clinical outcomes in patients with chronic decompensated cirrhosis.Methods: A prospective observational study was conducted on 90 patients with chronic decompensated cirrhosis. Serum sodium levels were measured, and patients were categorized into four groups: <125 mEq/L, 125-129 mEq/L, 130-134 mEq/L, and ≥135 mEq/L. The relationship between serum sodium levels and various clinical parameters, complications, mortality, hospital stay, and ICU requirement was analyzed. Results: The majority of patients (57.8%) were in the age group of 40-59 years, and males constituted 82.2% of the study population. Serum sodium levels showed a significant inverse correlation with ChildPugh scores (r=-0.723, p<0.001) and MELD scores (r=-0.739, p<0.001). Patients with lower serum sodium levels had a significantly higher prevalence of complications, including hepatorenal syndrome (18.8% in patients with serum sodium <125 mEq/L), spontaneous bacterial peritonitis (12.5%), hepatic encephalopathy (68.8%), and coagulopathy (81.3%). Lower serum sodium levels were also associated with increased mortality, prolonged hospital stay, and higher ICU requirement (p<0.001). Conclusion: Serum sodium is a valuable prognostic marker in patients with chronic decompensated cirrhosis. Lower serum sodium levels are associated with more advanced liver disease, higher prevalence of complications, increased mortality, prolonged hospital stay, and higher ICU requirement. Incorporating serum sodium levels into the assessment and management of these patients can aid in risk stratification and treatment decisions

Recommended Articles
Loading Image...
Volume-5, Issue-4
Citations
1781 Views
350 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved